Pfizer Reports Q2 Results, Raises Revenue Guidance, But Takes $4.3B Impairment Charge

summarizeSummary

Pfizer delivered mixed Q2 results, raising revenue guidance but reaffirming EPS guidance due to a $4.3 billion non-cash impairment charge and acquisition impacts, while also announcing new cost-saving initiatives.

check_boxKey Events · Earnings and Guidance · PFE

• Q2 Financials Reported

  Reported Q2 revenues of $15.0 billion, representing 1% operational growth (5% excluding COVID-19 products), and Adjusted Diluted EPS of $0.77.

• Full-Year Revenue Guidance Raised

  Full-year 2026 revenue guidance midpoint raised by $500 million to a range of $60.5-$62.5 billion, primarily due to better-than-expected performance of non-COVID products.

• Full-Year EPS Guidance Reaffirmed

  Full-year 2026 Adjusted Diluted EPS guidance reaffirmed at $2.80-$3.00, absorbing an approximate $0.10 unfavorable impact from the Innovent Biologics, Inc. transaction.

• $4.3 Billion Intangible Asset Impairment

  Recorded a significant non-cash intangible asset impairment charge of $4.3 billion, including $3.8 billion for sigvotatug vedotin (due to unfavorable Phase 3 clinical trial results) and $525 million for Oxbryta (no viable pathway to market).

auto_awesomeAnalysis · PFE · Life Sciences

Pfizer reported mixed second-quarter results, raising its full-year revenue guidance by $500 million at the midpoint, primarily driven by better-than-expected performance in non-COVID products. However, the company reaffirmed its adjusted EPS guidance, absorbing a $0.10 impact from a recent acquisition and reflecting a significant $4.3 billion non-cash intangible asset impairment charge related to a failed Phase 3 trial and an unviable product pathway. The company also announced additional long-term productivity savings.